December 14, 2024

AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say

 AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say

AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say

AbbVie’s “pain” is Bristol Myers Squibb’s “gain,” says Truist Securities analyst Srikripa Devarakonda.